Introduction
Severe respiratory virus infections typically include robust local host inflammatory responses that contribute to disease severity [1] . Immunomodulatory strategies designed to limit virus-induced inflammation may be of substantial therapeutic importance when no vaccines or broadly effective antivirals are available [2] .
Toward this end, there is significant interest in the immunomodulatory properties of clinically benign Grampositive Lactobacillus spp. and their role in promoting positive outcomes in acute respiratory virus infections [3] . To date, most of the focus in this field, both clinically and in mouse models, has been on how oral intake of specific probiotics, including Lactobacillus spp. may alter systemic inflammatory responses [4] . By contrast, we focused on delivery of live or inactivated preparations of Lactobacillus plantarum (Lp) directly to the respiratory tract, either before or immediately after virus inoculation. In other studies, we have shown that administration of Lp via this route results in full and sustained protection from the lethal sequelae of infection [5] [6] [7] [8] [9] . Specifically, Lp administered directly to the airways via either of these protocols mediates suppression of virus-induced proinflammatory cytokine production and leukocyte recruitment, responses that are dependent on coordinate activation of the pattern recognition receptors (PRRs) TLR2 and NOD2 [9] and that are B lymphocyte and antibody independent [7] . Lp administered to the respiratory mucosa also elicits full protection in mice with single gene deletions of IL-10, IFN-abR, IFN-g, CX 3 CR1, CCR2, and IL-17A [6, 8, and unpublished data], although the possibility of compensatory signaling among multiple pathways remains to be addressed. In mice protected by Lp, suppression of a specific subset of virus-induced proinflammatory mediators, primarily IL-6, but also CCL2 and CXCL10, is among the most profound and consistent responses [8] . Furthermore, we have found that administration of a characterized bifunctional TLR2-NOD2 ligand replicates much of the anti-inflammatory impact of Lp and likewise elicits protection against acute respiratory virus infection [9] . Several groups have explored similar examples of Lactobacillus-mediated cross-protection [10] [11] [12] , but the mechanisms underlying this response, and, more broadly, the ways in which bacteria, bacterial components, and PRR ligands administered to the respiratory tract promote protection against lethal virus infection remain to be fully elucidated.
To explore endogenous viral inflammation in a rodent host, our studies feature the natural rodent pathogen, pneumonia virus of mice (PVM). PVM is of the same virus family (Pneumoviridae) and genus (Orthopneumovirus [13] ) as human respiratory syncytial virus (HRSV). HRSV and PVM have genomes that are nonsegmented, negative-sense, single-stranded (ss)RNA, although there is little to no sequence homology between individual encoded proteins [14] . HRSV infects infants and the elderly worldwide [15] , although it does not undergo replication or elicit profound inflammatory pathology in inbred strains of mice. By contrast, PVM undergoes robust replication in mouse lung tissue, resulting in severe inflammatory disease in association with cytokine production and leukocyte recruitment to the airways. Acute PVM infection in mice replicates the inflammatory responses characteristic of the most severe forms of HRSV infection and serves as a clinically relevant in vivo model for evaluating anti-inflammatory and immunomodulatory therapeutic strategies [14] .
To date, we have focused on Lp at airways as an immunomodulatory agent, and we have explored its role in suppressing lethal inflammation in hosts with endogenous means of clearing virus from the respiratory tract. In this study, we explored the impact of Lp-mediated protection against lethal PVM infection in recombinase-deficient Rag1 2/2 mice [16] that lack all lymphocyte lineages. We find that administration of Lp can substantially delay the lethal sequelae of infection in the Rag1 2/2 strain, but these mice will ultimately succumb to lethal inflammation in association with ongoing virus replication and persistence in the lung tissue. Our findings illustrate clearly that Lp, as an immunomodulatory agent, is only fully effective in a setting in which there is effective endogenous virus clearance. More broadly, our findings suggest that manipulation of the host inflammatory response alone may determine whether a respiratory virus infection is lethal or benign in an otherwise immunocompetent host. were from the Jackson Laboratory (Bar Harbor, ME, USA). All mice were within 6-9 wk of age at the start of each experiment, and we used both male and female mice. Wild-type (WT) and gene-deleted mice were age and gender matched within a given set of experiments The NIAID Division of Intramural Research Animal Care and Use Program, as part of the NIH Intramural Research Program, approved all of the experimental procedures (protocol LAD 8E).
MATERIALS AND METHODS

Mice
Virus preparation and titration
Titers of mouse-passaged stocks of PVM strain J3666 were determined by TCID 50 assay as previously described [17] . Infections were established via intranasal (i.n.) inoculation of isoflurane-anesthetized mice with 2.0 TCID 50 units in 50 ml of IMDM. Virus recovery from whole lung and spleen tissue was evaluated using the dual-standard curve qRT-PCR method previously described [18] with primer probes targeting the PVM small hydrophobic gene and cellular GAPDH.
Lactobacillus preparation and inoculations
All experiments were performed with heat-inactivated Lp NCIMB 8826 (ATCC BAA-793), prepared as described elsewhere [9] and stored at 280°C at 10 11 cell equivalents/ml in PBS with 0.1% BSA. Isoflurane-anesthetized mice were inoculated i.n. with 50 ml Lp at 2 3 10 9 cell equivalents/ml 
Detection of Lp genomic DNA
Detection of Lp genomic (g)DNA in lung tissue was performed as described [19] . Lungs from mice inoculated with Lp were stored at 280°C in RNAlater (Thermo Fisher Scientific); gDNA was isolated and evaluated on an ABI 7500 Real Time PCR system (Thermo Fisher Scientific), with primers and probe designed to detect the Lp 16s-23s intergenic region as described [20] , including forward primer, 59-TGG ATC ACC TCC TTT CTA AGG AAT-39; reverse primer, 59-TGT TCT CGG TTT CAT TAT GAA AAA ATA-39; and probe, 59-ACA TTC TTC GAA ACT TTG T-39-MGB and calibrated via interpolation to standard curves. 
ELISAs
Quantitative analysis of cytokine mediators in BAL fluid and mouse lung tissue homogenates was performed by ELISA with kits purchased from R&D Systems (Minneapolis MN, USA) and Abcam (Cambridge MA, USA) and used according to the manufacturers' instructions. Mediator levels in mouse lung tissue homogenates were corrected for total protein with a BCA assay (Thermo Fisher Scientific).
Statistics
All quantitative findings were from 2 to 3 replicate datasets. Data were analyzed via algorithms (log-rank, 2-way ANOVA, Mann-Whitney U test) with Prism 7.0 (GraphPad, San Diego, CA, USA).
RESULTS AND DICUSSION
Immunobiotic Lp delivered directly to the respiratory tract delays but does not prevent lethal sequelae of PVM infection in lymphocyte-deficient Rag1 2/2 mice
We have shown that delivery of immunobiotic Lp directly to the respiratory tract, either before [5] or immediately after [8] inoculation with PVM, results in full protection from the lethal inflammatory sequelae of this infection. Of specific relevance to this work, we have shown that the actions of Lp are not mediated by antibodies or B lymphocytes. Lp administered to the respiratory mucosa results in inflammatory suppression and full protection against lethal PVM infection in B-cell-deficient mMT and Jh mice [7] .
In the present study, we examined the impact of Lp at the respiratory mucosa in mice unable to clear PVM virions. PVM clearance from lung tissue has been examined by Frey et al. [21] , who determined that this response was promoted in vivo by CD4 + and CD8 + T lymphocytes. Although administration of Lp typically results in small reductions (;0.5-1.0 log) in virus recovery at peak illness [5, 7] , we found that virus titer is not a clear or definitive indicator of clinical outcome in Lp-treated mice [5] . We therefore performed experiments to determine whether the anti-inflammatory impact of Lp would be sustained in the face of moderate to long-term virus persistence in the airways and whether Lp facilitates virus clearance via some alternative mechanism.
As shown in Fig. 1A , i.n. inoculation with heat-inactivated Lp on days 1 and 2 after inoculation with PVM on day 0 resulted in full, long-term protection from lethal sequelae of infection in WT mice, but only temporary protection in lymphocyte-deficient Rag1 2/2 mice. Analogous results-complete, but ultimately only temporary protection-were obtained upon treatment of PVMinfected Rag1 2 /2 mice with the TLR2-NOD2 ligand CL429, which promotes survival and suppression of virus-induced inflammation at the respiratory mucosa in WT mice [9; Supplemental Fig. 1 ]. Rag1 2 /2 mice, similar to WT mice [8] , respond to acute PVM infection with local production of the proinflammatory cytokine, IL-6; CCL2 and CXCL10 were also detected, albeit at substantially lower levels, shown here at day 7 (Fig. 1B) . Administration of Lp to the respiratory mucosa resulted in dramatic suppression of IL6 in both WT and Rag1 2 /2 mice (30-fold and 53-fold, respectively); suppression of CXCL10 is significant, but less profound at this time point. Results analogous to those shown in Fig. 1A were obtained when Lp was administered before PVM infection (Lp on days 214 and 27 before virus was introduced on day 0). As in Fig. 1A , the lethal sequelae of PVM infection was significantly delayed but ultimately not prevented in Rag1 2/2 mice (Fig. 1C) .
Immunomodulatory responses at the respiratory tract cannot be reproduced by administration of Lp by oral gavage in the postexposure model. There is substantial interest in the antiinflammatory impact of Lactobacillus spp. in the gastrointestinal tract [4, 22, 23] , although there is no clear evidence to date that oral intake has significant effect on critical outcome measures of acute respiratory virus infection [3, 24] . We have shown that live Lp provided to mice (10 9 CFU/ml) in drinking water for 2 wk before virus inoculation and throughout the infection period results in no protection against lethal infection [7] . In the present study, we extend this result: whereas Lp administered to the respiratory tract (10 8 bacterial cell equivalents per dose intranasally on days 1 and 2) resulted in full protection, the same dose (10 8 bacterial cell equivalents administered orally by gavage on days 1 and 2 as shown) provided no protection over diluent control in this model (Supplemental Fig. 2 ). We conclude from these results that Lp administered via the i.n. route in this protocol is exerting its impact at the respiratory tract, not the gastrointestinal tract. We cannot rule out the possibility that a small fraction of the i.n. inoculum may have been swallowed and thus inadvertently administered to the gastrointestinal tract, we effectively ruled out that this possibility would be of any consequence with respect to the protective mechanisms examined. We conclude that swallowed inoculum would have no effect, because as we show herein, administration of the entire 10 8 bacterial cell inoculum directly to the gastrointestinal tract via oral gavage resulted in no significant protection over diluent control. However, the possibility that other gavage protocols with other Lactobacillus spp. prepared and administered in different protocols may yield different results is not ruled out. were devoid of lymphoid lineage T, B, and NK T cells (Supplemental Fig. 3 ). PVM was detected in lung tissue of Lp-treated WT mice at days 2, 5, 6, and 7, but at no time points thereafter ( Fig. 2A) . By contrast, PVM was detected on days 10 and 12 and 19, 20, and 21 in lung tissue of PVM-infected, Lp-treated Rag1 2/2 mice, with evidence of replication in situ.
Despite its persistence in lung tissue, we found no evidence of release of PVM in the systemic circulation of spleen tissue (Fig.  2B) . Virus was not effectively cleared, but Lp gDNA was cleared efficiently from Lp-treated, PVM-infected Rag1 2/2 and from WT mice (Fig. 2C) . Differential clearance is unlikely to be associated with secondary inflammation in Rag1 2/2 mice. The clearance findings are similar to those reported by Garcia-Crespo et al. [6] who found that that gDNA from live Lactobacillus reuteri was no longer detectable within 96 h of i.n. administration. Ma et al. [19] also reported rapid clearance of gDNA from both live and inactivated Lp.
Delayed pulmonary inflammation in Lp-treated PVM-infected Rag1 2/2 mice. Although Lp treatment effectively suppresses the primary inflammatory response characteristic of acute PVM infection in both strains, in the current study, persistent virus in lung tissue of Rag1 2/2 mice ultimately provoked a delayed inflammatory response immediately preceding death. Histologic sections from Lp-treated WT and Rag1 2/2 mice on day 20 after inoculation with PVM are shown in Fig. 3A and B, respectively. The alveoli in lung tissue of WT mice are free of cellular infiltrate, whereas granulocytes infiltrate the alveoli of Rag1 (Fig. 3C) . Consistent with histology, we observed an increase in the neutrophils and eosinophils in the Lp-treated, PVM-infected Rag1 2/2 mice, but not in the WT mice. Relative expression of proinflammatory mediators in whole-lung tissue examined by qPCR revealed up-regulated expression of the CC chemokines CCL1, -2, -7, and -12 and the CXC chemokines CXCL9, CXCL10, and -13 in Rag1 2/2 vs. WT controls (Fig. 3D) ; differential expression of immunoreactive CCL1, -2, and -7 were confirmed by ELISA (Fig. 3E ). Apart from CCL12, which is a prominent eosinophil chemoattractant, the other chemokines are primarily chemoattractants for monocytes and T cells, although CCL7 has been characterized as having broad activities on a range of myeloid and lymphoid cells, as discussed further below. Although seemingly counterintuitive, these findings can be considered in light of recent observations of Cortjens et al. [25] who reported that, whereas granulocyte recruitment is a prominent characteristic PVM infection, antibody-mediated neutrophil depletion has no direct impact on the lethal sequelae of infection. These results are an intriguing contrast to those described earlier by Domachowske et al. [26] in mice devoid of the CCL3/CCR1 signaling axis. In these latter studies, mice unable to recruit neutrophils or eosinophils fared somewhat less well in response to lethal PVM infection than their WT counterparts. Apart from neutrophils, the role of eosinophils and their interactions with respiratory viruses is also worthy of further consideration (reviewed in ref. 27 ). Virus persistence in lung tissue and the associated delayed inflammatory response in PVM-infected Rag-1 2/2 mice did not result production of type I IFNs (Fig. 3E) . The role of type I IFNs in Lp-mediated primary protection against the lethal sequelae of PVM infection is considered in the section to follow. Mice devoid of IFN-abR respond to Lp and are fully protected from the lethal sequelae of PVM infection. As shown in Fig. 4A , IFN-abR 2/2 mice were protected by Lp at the respiratory mucosa, with a 10-fold lower inoculum than that used in our earlier study [8] . Administration of Lp results in suppression of neutrophil recruitment to the airways in both WT and IFNabR 2/2 mice (Fig. 4B) . As reported previously [28] mice, analogous to WT (Fig. 4C) . Similarly, Lp treatment resulted in suppression of the critical cytokines IL-6 and CCL2 in PVM-infected IFN-abR 2/2 and WT mice; differential expression of CXCL10 and IFN-a was observed in WT mice only (Fig.  4D) . Overall, we conclude that IFN-abR-mediated signaling is not a critical, nonredundant feature of the primary protective response to Lp at the respiratory mucosa. This conclusion is discussed further below. CD8 + T cells, virus clearance, and secondary inflammation. As noted above, the role of T cells in promoting clearance of PVM was addressed directly by Frey et al. [21] who found that CD4 + and CD8 + T cells promoted virus clearance from the respiratory tract via actions that were functionally redundant. Consistent with these observations, we found that Lp-primed CD8 null mice were fully protected against the lethal sequelae of PVM infection (Fig. 5A) . Full virus clearance was observed by day 19 in both CD8 null and WT mice (Fig. 5B) , and few to no neutrophils or eosinophils were detected in the airways (Fig. 5C ). Cytokine mediators were evaluated in BAL fluid, as was performed previously in Rag1 2/2 mice (Fig. 5D) . In contrast to what was observed in Rag1 2/2 vs. WT mice (Fig. 3E) , little or no CCL7 was detected in the airways of PVM-infected, Lp-treated CD8 null mice at day 19. Perhaps even more interesting, elevated levels of CCL1 and -2 were detected in the airways of CD8 null mice despite full virus clearance in both strains. CCL7 (also known as MCP-3) interacts with CC chemokine receptors CCR1, -2, -3 and -5 and activates a broad range of proinflammatory leukocytes [29] . Most recently, Girkin et al. [30] found that CCL7 was a major Despite their positive role in promoting virus clearance, the role of CD8 + T cells in PVM infection may be more of a doubleedged sword. Specifically, Walsh et al. [31] found that CD8 + T cells recruited in response to PVM infection initiated a lethal cytokine storm that could be modulated by addition of anticytokine antibodies and the sphingosine-1-phosphate receptor 1 (S1P1R) agonist alone or in conbination. Likewise, Frey et al. [32] examined the in situ generation of CD8 + CTLs, which intriguingly, reach peak numbers in the lung coinciding with peak clinical disease. Moreoever, Claassen et al. [33] , reported that, despite the influx of CD8 + T cells accompanying acute infection, PVM suppressed the generation of and cytokine secretion from epitope-specific antiviral CD8 + T cells. As shown in Fig. 5A , survival of Lp-naive CD8 null mice is significantly prolonged compared to Lp-naive WT counterparts, a finding that also suggests that CD8 + T cells contribute to PVM-induced inflammatory disease, consistent with the aforementioned observations. As shown in our microarray study of whole-lung tissue from Lp-vs. diluent-treated, PVM-infected WT mice, among the factors suppressed by Lactobacillus priming, we found the T cell-associated mediators granzyme B and IFN-g and also sphingosine 1-kinase [8; see GSE66721] .
Delayed lethal response observed in Lp-treated Rag1 2/2 mice was refractory to further treatment. As shown earlier, PVMinfected WT mice treated with Lp are fully protected, whereas the lethal inflammatory sequelae are delayed in Rag1 2/2 mice.
Although all Lp-treated PVM-infected Rag1 2/2 mice survive significantly longer than PVM-infected counterparts that received diluent only, additional doses of Lp provided at weekly intervals before day 20 offered no further survival advantage (Fig. 6A) . The results of this study expand our understanding of Lp-mediated cross-protection at the respiratory mucosa and emphasize the role of Lp as a local immunomodulatory mediator. As of this writing, there are numerous examples of cross-protection achieved with live bacteria, inactivated bacteria, bacterial components, and bacterial PRR ligands used to combat respiratory virus infections (reviewed in [34, 35] ). A wide variety of both complementary and distinct mechanisms have been implicated, which may relate in part to differences in bacterial species, strains, and preparations used and the complexities introduced by differences in target virus pathogens. For example, Wiley et al. [36] reported that administration of protein nanoparticles generated from the thermophilic Methanocaldococcus jannaschii generated cross-protection against numerous respiratory viruses, including PVM, via a mechanism directly dependent on B cells and antibodies in airways, a finding that invokes a mechanism is in direct contrast to what we have observed in response to protection elicited by Gram-positive L. plantarum. Likewise, Schnoeller et al. [37] found that i.n. administration of an attenuated strain of Gram-negative Bordetella pertussis elicited IL-17-dependent protection against primary RSV challenge in mice via a mechanism directly related to reductions in virus load. Similarly, Tuvim et al. [38, 39] examined the impact of nontypeable Haemophilus influenzae and ligands for PRRs TLR2/6 and -9 on the outcome of influenza A H3N2 infection and likewise found primary correlation with reduction in virus titer, in contrast to our findings, which identify both Lp and cognate TLR2-NOD2 ligands as primarily immunomodulatory, with little direct impact on virus replication per se. Drake et al. [40] likewise used prophylaxis with TLR2/6 and TLR9 agonists in a guinea pig model of Sendai virus infection and noted reductions in virus titer, but no impact on virus-induced airway dysfunction.
CONCLUSION
We conclude from this study that immunobiotic Lp at the respiratory mucosa substantially delays but does not prevent the lethal inflammatory sequelae secondary to acute PVM infection in lymphocyte-deficient Rag1 2/2 mice. After a significant delay (20-25 d after inoculation with PVM), production of inflammatory cytokines, leukocyte recruitment to the alveoli, lung edema, and mortality were observed in association with persistent virus in Lp-treated Rag1 2/2 mice. Repeated doses of Lp had no impact on this outcome. The results from our studies in Rag1 2/2 mice reported here, together with those from our earlier work [5] [6] [7] [8] [9] , permit us to draw the following conclusions:
1. Immunobiotic Lp administered to the respiratory tract functions as an immunomodulatory agent that promotes suppression of the lethal virus-induced cytokine storm. The immunomodulatory actions of Lp serve to suppress lethal virus-induced inflammation during the course of replication and clearance in an immunocompetent host. Similarly, in an otherwise immunocompetent host, it is the inflammatory response that defines the nature of the virus infection, as manipulation of this response in vivo can convert a lethal respiratory virus infection into one that is functionally benign. 2. In the absence of virus clearance, this balance is disrupted.
As the immunomodulatory impact of Lp wanes, inflammation re-emerges in response to virus that persists in the airways. 3. Nonetheless, rational design of immunomodulatory mediators that limit lethal virus-induced inflammation may be of substantial therapeutic importance, notably with respect to emerging respiratory virus pathogens and absence of specific antiviral vaccines. 
